Thorburn DR. Mitochondrial disorders:prevalence, myths and advances[J]. J Inherit Metab Dis, 2004, 27(3):349-362.
[2]
Yamamoto H, Tang HW. Preventive effect of melatonin against cyanide-induced seizures and lipid peroxidation in mice[J]. Neurosci Lett, 1996, 207(2):89-92.
Kunz WS. The role of mitochondria in epileptogenesis[J]. Curr Opin Neurol, 2002, 15(2):179-184.
[5]
Harris MO, Walsh LE, Hattab EM, et al. Is it ADEM, POLG, or both[J]. Arch Neurol, 2010, 67(4):493-496.
[6]
Rahman S, Clarke CF, Hirano M. 176th ENMC International Workshop:diagnosis and treatment of coenzyme Q10 deficiency[J]. Neuromuscul Disord, 2012, 22(1):76-86.
[7]
Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA[J]. Metab Brain Dis, 2007, 22(1):105-109.
[8]
Lam CW, Lau CH, Williams JC, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy[J]. Eur J Pediatr, 1997, 156(7):562-564.
[9]
Galimberti CA, Diegoli M, Sartori I, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation[J]. Neurology, 2006, 67(9):1715-1717.
[10]
Chabrol B, Mancini J, Chretien D, et al. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency[J]. Eur J Pediatr, 1994, 153(2):133-135.
[11]
Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations:EEG and MRI features[J]. Epilepsia, 2009, 50(6):1596-1607.
[12]
Isohanni P, Hakonen AH, Euro L, et al. POLG1 manifestations in childhood[J]. Neurology, 2011, 76(9):811-815.
[13]
Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus[J]. Epilepsia, 2008, 49(6):1038-1045.
[14]
Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity[J]. Clin Toxicol (Phila), 2009, 47(2):101-111.
[15]
Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome[J]. J Neurol Sci, 2006, 243(1-2):97-99.
[16]
Arpin S, Lagrue E, Bodard S, et al. Basal ganglia neuroprotection with anticonvulsants after energy stress:a comparative study[J]. Metab Brain Dis, 2009, 24(3):453-461.
[17]
Koga Y, Akita Y, Nishioka J, et al. MELAS and L-arginine therapy[J]. Mitochondrion, 2007, 7(1-2):133-139.
[18]
Pineda M, Ormazabal A, Lopez-Gallardo E, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion[J]. Ann Neurol, 2006, 59(2):394-398.
[19]
Chinnery P, Majamaa K, Turnbull D, et al. Treatment for mitochondrial disorders[J]. Cochrane Database Syst Rev, 2006, 25(1):CD004426.
[20]
El Sabbagh S, Lebre AS, Bahi-Buisson N, et al. Epileptic phenotypes in children with respiratory chain disorders[J]. Epilepsia, 2010, 51(7):1225-1235.
[21]
Kim DY, Simeone KA, Simeone TA, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition[J]. Ann Neurol, 2015, 78(1):77-87.
[22]
Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects:underlying etiology in various epileptic conditions[J]. Epilepsia, 2008, 49(4):685-690.
[23]
Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects[J]. Epilepsia, 2007, 48(1):82-88.
[24]
Alpers BJ. Diffuse progressive degeneration of the gray matter of the cerebrum[J]. Arch Neurol Psychiatry, 1931, 25(3):469-505.
[25]
Huttenlocher PR, Solitare GB, Adams G. Infantile diffuse cerebral degeneration with hepatic cirrhosis[J]. Arch Neurol, 1976, 33(3):186-192.
[26]
Naviaux RK, Nyhan WL, Barshop BA, et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers syndrome[J]. Ann Neurol, 1999, 45(1):54-58.
[27]
Graziewicz MA, Longley MJ, Bienstock RJ, et a1. Structure-function defects of human mitoehondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia[J]. Nat Struct Mol Biol, 2004, 11(8):770-776.
[28]
Rovio AT, Abel J, Ahola AL, et a1. A prevalent POLG CAG microsatellite length allele in humans and African great apes[J]. Mamm Genome, 2004, 15(6):492-502.
Darin N, Oldfors A, Moslemi AR, et al. The incidence of mitochondrial encephalomyopathies in childhood:clinical features and morphological, biochemical, and DNA abnormalities[J]. Ann Neurol, 2001, 49(3):377-383.
[31]
Wong LJ, Naviaux RK, Brunetti-Pierri N, et a1. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations[J]. Hum Mutat, 2008, 29(9):E150-E172.